Dr. Alan Bryce on Molecular Testing in Metastatic or High-Risk Stage III Melanoma

Video

In Partnership With:

Alan H. Bryce, MD, medical oncologist, Mayo Clinic, discusses the need for molecular testing in patients with metastatic or high-risk stage III melanoma.

Alan H. Bryce, MD, medical oncologist, Mayo Clinic, discusses the need for molecular testing in patients with metastatic or high-risk stage III melanoma.

There are various professional opinions on when molecular testing is appropriate for these patients, Bryce explains. However, by doing comprehensive sequencing of tumors at each stage, researchers are able to gather more knowledge on decreasing the risk of disease recurrence by defining who does not require treatment. It also increases benefit to patients by accelerating drug development.

From an economic perspective, Bryce explains that because molecular testing is expensive, patient selection is imperative.

Ultimately, Bryce says, clinicians should decide if molecular testing is necessary for a patient's situation and how high his/her risk is of disease recurrence. Frequently, both clinicians and patients will decide that molecular testing is needed, he says.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute